Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324009 | 0.90 | TSHR (0.56) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6325690 | 0.83 | ALDH1A1 (0.67) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6325165 | 0.80 | TSHR (0.76) | TSHRALDH1A1MCL1ATMLMNA | |
| SCHEMBL6325487 | 0.80 | TSHR (0.67) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6326164 | 0.78 | ALDH1A1 (0.63) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6326409 | 0.78 | ALDH1A1 (0.60) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6326301 | 0.77 | TSHR (0.63) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL6324077 | 0.77 | MCL1 (0.60) | TSHRALDH1A1CYP3A4HPGDMCL1 | |
| SCHEMBL13781596 | 0.76 | HCAR2 (0.65) | TSHRALDH1A1MCL1ATMLMNA | |
| SCHEMBL6328228 | 0.74 | ALDH1A1 (0.65) | TSHRALDH1A1CYP3A4HPGDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | TSHR 4656/4885ALDH1A1 338/4885CYP3A4 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.